A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis; Pain
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EM-II; Solstice
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Sep 2017 According to an Abbvie media release, has submitted a New Drug Application (NDA) to the US FDA for elagolix for the management of endometriosis with associated pain.
    • 03 Aug 2017 According to a AbbVie media release, data from this trial was published in the New England Journal of Medicine
    • 03 Aug 2017 Acoording to a AbbVie media release, data from this trial was presented at the 13th World Congress on Endometriosis 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top